These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33609771)

  • 1. Immune-related cutaneous adverse events due to checkpoint inhibitors.
    Wang E; Kraehenbuehl L; Ketosugbo K; Kern JA; Lacouture ME; Leung DYM
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):613-622. PubMed ID: 33609771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related cutaneous adverse events: A new opportunity for allergists and clinical immunologists.
    Leung DYM
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):607. PubMed ID: 34049668
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune-related dermatologic toxicities: to make a long story short.
    Angelaki A; Lampropoulou DI; Aravantinos G
    Cutan Ocul Toxicol; 2020 Mar; 39(1):10-12. PubMed ID: 31648558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
    Pach J; Valido K; Belzer A; Leventhal JS
    Am J Clin Dermatol; 2024 Jul; 25(4):595-607. PubMed ID: 38767827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
    J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer.
    Thompson LL; Nadelmann ER; Blum AE; Yoon J; Polyakov NJ; Kagan RD; Gainor JF; Mooradian MJ; Chen ST
    Eur J Cancer; 2021 Apr; 147():13-16. PubMed ID: 33607381
    [No Abstract]   [Full Text] [Related]  

  • 13. Why are immune adverse events so common with checkpoint inhibitor therapy?
    Lyubchenko T; Leung DYM; Goleva E
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
    Nadelmann ER; Yeh JE; Chen ST
    JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare, but Severe: Vasculitis and Checkpoint Inhibitors.
    Lindner AK; Gruenbacher G; Schachtner G; Thurnher M; Pichler R
    Eur Urol Focus; 2020 May; 6(3):609-612. PubMed ID: 31072806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
    Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
    J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization.
    Labella M; Castells M
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):623-629. PubMed ID: 33781937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.